LU93015I2 - Carfilzomib eventuellement sous forme d'un sel pharmaceutiquement acceptable - Google Patents

Carfilzomib eventuellement sous forme d'un sel pharmaceutiquement acceptable Download PDF

Info

Publication number
LU93015I2
LU93015I2 LU93015C LU93015C LU93015I2 LU 93015 I2 LU93015 I2 LU 93015I2 LU 93015 C LU93015 C LU 93015C LU 93015 C LU93015 C LU 93015C LU 93015 I2 LU93015 I2 LU 93015I2
Authority
LU
Luxembourg
Prior art keywords
peptide
carfilzomib
possibly
based compounds
activities
Prior art date
Application number
LU93015C
Other languages
English (en)
Original Assignee
Onyx Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35502451&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU93015(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Onyx Therapeutics Inc filed Critical Onyx Therapeutics Inc
Publication of LU93015I2 publication Critical patent/LU93015I2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • AIDS & HIV (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
LU93015C 2004-08-06 2016-04-06 Carfilzomib eventuellement sous forme d'un sel pharmaceutiquement acceptable LU93015I2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US59940104P 2004-08-06 2004-08-06
US61000104P 2004-09-14 2004-09-14
US11/106,879 US7232818B2 (en) 2004-04-15 2005-04-14 Compounds for enzyme inhibition
PCT/US2005/028246 WO2006017842A1 (fr) 2004-08-06 2005-08-08 Composes pour l'inhibition enzymatique du proteasome

Publications (1)

Publication Number Publication Date
LU93015I2 true LU93015I2 (fr) 2016-06-06

Family

ID=35502451

Family Applications (1)

Application Number Title Priority Date Filing Date
LU93015C LU93015I2 (fr) 2004-08-06 2016-04-06 Carfilzomib eventuellement sous forme d'un sel pharmaceutiquement acceptable

Country Status (25)

Country Link
US (12) US7232818B2 (fr)
EP (4) EP1781688B1 (fr)
JP (2) JP4743720B2 (fr)
KR (3) KR101544258B1 (fr)
CN (1) CN102286070B (fr)
AT (1) ATE496062T1 (fr)
AU (1) AU2005271232B2 (fr)
BR (2) BRPI0514102B8 (fr)
CA (1) CA2589765C (fr)
CY (3) CY1116771T1 (fr)
DE (1) DE602005026019D1 (fr)
DK (2) DK1781688T3 (fr)
ES (2) ES2674277T3 (fr)
FR (1) FR16C0017I2 (fr)
HK (4) HK1103525A1 (fr)
HU (2) HUE038005T2 (fr)
IL (3) IL181127A (fr)
LT (2) LT3101026T (fr)
LU (1) LU93015I2 (fr)
NO (2) NO341015B1 (fr)
PL (2) PL3101026T3 (fr)
PT (2) PT3101026T (fr)
SG (2) SG10201701794UA (fr)
SI (2) SI3101026T1 (fr)
WO (1) WO2006017842A1 (fr)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7176232B2 (en) 2002-06-24 2007-02-13 The Regents Of The University Of California Salinosporamides and methods for use thereof
AU2005238445B2 (en) 2004-04-15 2012-05-03 Onyx Therapeutics, Inc. Compounds for enzyme inhibition
US8198270B2 (en) * 2004-04-15 2012-06-12 Onyx Therapeutics, Inc. Compounds for proteasome enzyme inhibition
US7232818B2 (en) * 2004-04-15 2007-06-19 Proteolix, Inc. Compounds for enzyme inhibition
ES2510840T3 (es) 2004-05-10 2014-10-21 Onyx Therapeutics, Inc. Compuestos para la inhibición enzimática del proteosoma
WO2005111009A2 (fr) * 2004-05-10 2005-11-24 Proteolix, Inc. Synthese de ceto-epoxydes d'acides amines
CN101155582B (zh) 2004-12-03 2013-04-24 达纳-法伯癌症研究公司 治疗肿瘤性疾病的组合物和方法
ATE499109T1 (de) 2004-12-07 2011-03-15 Proteolix Inc Zusammensetzung zur proteasomhemmung
PL2623113T3 (pl) 2005-11-09 2018-05-30 Onyx Therapeutics, Inc. Związek do hamowania enzymu
EP2484688B1 (fr) 2006-06-19 2016-06-08 Onyx Therapeutics, Inc. Peptide époxycétones destinées à l'inhibition de proteasome
EP2040694A2 (fr) * 2006-07-14 2009-04-01 VIB vzw Utilisation d'agonistes des ppar-alpha pour le traitement de troubles du dépérissement des muscles squelettiques
US7642369B2 (en) * 2006-09-12 2010-01-05 University Of Kentucky Research Foundation Epoxyketone-based immunoproteasome inhibitors
AU2013203566B2 (en) * 2007-10-04 2016-10-13 Onyx Therapeutics, Inc. Crystalline peptide epoxy ketone protease inhibitors and the synthesis of amino acid keto-epoxides
AU2016231532B2 (en) * 2007-10-04 2018-05-10 Onyx Therapeutics, Inc. Crystalline peptide epoxy ketone protease inhibitors and the synthesis of amino acid keto-epoxides
US8367617B2 (en) 2007-10-04 2013-02-05 Onyx Therapeutics, Inc. Crystalline peptide epoxy ketone protease inhibitors and the synthesis of amino acid keto-epoxides
US8394816B2 (en) * 2007-12-07 2013-03-12 Irene Ghobrial Methods of using [3.2.0] heterocyclic compounds and analogs thereof in treating Waldenstrom's Macroglobulinemia
EP2088205A1 (fr) 2008-02-11 2009-08-12 Institut National De La Sante Et De La Recherche Medicale (Inserm) PSMB10 : marqueur de diagnostic et cible thérapeutique de rejet chronique
US7635773B2 (en) 2008-04-28 2009-12-22 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions
CN102089312A (zh) 2008-05-12 2011-06-08 尼瑞斯药品公司 作为蛋白酶体抑制剂的Salinosporamide衍生物
EP3090737A1 (fr) 2008-10-21 2016-11-09 Onyx Therapeutics, Inc. Thérapie de combinaison avec peptides d'époxycétones
AR075899A1 (es) 2009-03-20 2011-05-04 Onyx Therapeutics Inc Tripeptidos epoxicetonas cristalinos inhibidores de proteasa
US20110009332A1 (en) * 2009-07-09 2011-01-13 Southwest Research Institute Therapeutic Treatment Of Wounds
GB0914883D0 (en) 2009-08-26 2009-09-30 Univ Belfast Compound
US8853147B2 (en) 2009-11-13 2014-10-07 Onyx Therapeutics, Inc. Use of peptide epoxyketones for metastasis suppression
JP6042724B2 (ja) 2010-03-01 2016-12-14 オニキス セラピューティクス， インク．Ｏｎｙｘ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． イムノプロテアソーム阻害のための化合物
EP2555621A4 (fr) 2010-04-07 2014-07-02 Onyx Therapeutics Inc Inhibiteur d'immunoprotéasome de peptide époxycétone cristallin
US9126997B1 (en) 2010-09-07 2015-09-08 Northwestern University Synergistic effect of glucocorticoid receptor agonists in combination with proteosome inhibitors for treating leukemia and myeloma
US9272014B2 (en) 2011-03-29 2016-03-01 Texas Tech University System Galectin-3C combination therapy for human cancer
WO2013009923A1 (fr) * 2011-07-13 2013-01-17 Creighton University Procédés de favorisation de la croissance de neurones
US20150184246A1 (en) 2011-11-11 2015-07-02 Millennium Pharmaceuticals, Inc. Biomarkers of response to proteasome inhibitors
EP2776043B1 (fr) 2011-11-11 2018-02-21 Millennium Pharmaceuticals, Inc. Biomarqueurs de la sensibilité à des inhibiteurs du protéasome
EP2810066B1 (fr) 2012-01-24 2019-07-31 Millennium Pharmaceuticals, Inc. Méthodes de traitement du cancer
DK2814849T3 (da) 2012-02-15 2020-03-09 Cydex Pharmaceuticals Inc Fremgangsmåde til fremstilling af cyclodextrin-derivater
KR20190137963A (ko) * 2012-05-08 2019-12-11 오닉스 세라퓨틱스, 인크. 펩티드 프로테아좀 억제제 제제화를 위한 사이클로덱스트린 복합체화 방법
TW201414751A (zh) 2012-07-09 2014-04-16 歐尼克斯治療公司 肽環氧酮蛋白酶抑制劑之前驅藥物
JP2015524411A (ja) 2012-07-18 2015-08-24 オニキス セラピューティクス， インク．Ｏｎｙｘ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． エポキシケトン系プロテアソーム阻害剤のリポソーム組成物
US20150218212A1 (en) * 2012-08-21 2015-08-06 Fluorinov Pharma Inc. Fluorinated epoxyketone-based tetrapeptide compounds and uses thereof as proteasome inhibitors
CA2888822C (fr) 2012-10-22 2021-01-26 Cydex Pharmaceuticals, Inc. Compositions de cyclodextrine alkylee et procedes de preparation et d'utilisation de celles-ci
PL2968555T3 (pl) 2013-03-13 2020-11-16 Sanofi Kompozycje zawierające przeciwciała anty-cd38 i karfilzomib
AR095426A1 (es) 2013-03-14 2015-10-14 Onyx Therapeutics Inc Inhibidores tripeptídicos de la epoxicetona proteasa
AU2014240122B2 (en) 2013-03-14 2019-02-14 Onyx Therapeutics, Inc. Dipeptide and tripeptide epoxy ketone protease inhibitors
AU2014290012B2 (en) 2013-07-19 2020-01-16 Onyx Therapeutics, Inc. Peptide epoxyketone proteasome inhibitors in combination with PIM kinase inhibitors for treatment of cancers
CN103360348B (zh) * 2013-07-25 2015-06-24 苏州鹏旭医药科技有限公司 一种Carfilzomib中间体及其制备方法和制备Carfilzomib的方法
CA2920220A1 (fr) * 2013-09-06 2015-03-12 Sandoz Ag Synthese de cetones epoxy peptidiques
CN105517998A (zh) * 2013-09-06 2016-04-20 桑多斯股份公司 通过曼尼希反应立体选择性合成二醇和三醇以及它们在卡非佐米合成中的用途
WO2015121769A1 (fr) 2014-02-13 2015-08-20 Ranbaxy Laboratories Limited Procédé pour la préparation de méthyl n-[(benzyloxy)-carbonyl]-l-leucyl-l-phénylalaninate
CN103864889B (zh) * 2014-04-04 2017-01-11 重庆泰濠制药有限公司 环氧酮化合物、其制备方法及卡非佐米的制备方法
JP6914188B2 (ja) 2014-08-22 2021-08-04 サイデックス・ファーマシューティカルズ・インコーポレイテッド 分画アルキル化シクロデキストリン組成物ならびにその調製方法および使用方法
WO2016046843A1 (fr) 2014-09-24 2016-03-31 Biophore India Pharmaceuticals Pvt. Ltd. Procédé pour la préparation de (s)-4-méthyl-n- ((s)-1-(((s)-4-méthyl-1-((r)-2-méthyloxiran-2-yl)-1-oxo-pentan-2-yl)amino)-1-oxo-3-phénylpropan-2-yl)-2-((s)-2-(2-morpholinoacétamido)-4-phénylbutanamido) pentanamide
US20160115198A1 (en) 2014-10-27 2016-04-28 Apicore Us Llc Methods of making carfilzomib and intermediates thereof
CN104402973A (zh) * 2014-11-24 2015-03-11 重庆泰濠制药有限公司 一种卡非佐米无定型晶的制备方法
ES2742196T3 (es) 2014-12-02 2020-02-13 Fresenius Kabi Oncology Ltd Un procedimiento para la purificación de carfilzomib
US10301353B2 (en) 2014-12-31 2019-05-28 Dr. Reddy's Laboratories Limited Co-crystal of carfilzomib with maleic acid and process for the preparation of pure carfilzomib
US10544189B2 (en) 2015-04-22 2020-01-28 Msn Laboratories Private Limited Process for the preparation of (2S)-N-((S)-1-((S)-4-methyl-1-((R)-2-methyl oxiran-2-yl)-1-oxopentan-2-ylcarbamoyl)-2-phenylethyl)-2-((S)-2-(2-morpholinoacetamido)-4-phenylbutanamido)-4-methylpentanamide
EP3297678B1 (fr) 2015-05-21 2021-07-07 Laurus Labs Limited Procédé perfectionné de préparation de carfilzomib ou de sels pharmaceutiquement acceptables de celui-ci
CN106317188A (zh) * 2015-06-18 2017-01-11 重庆医药工业研究院有限责任公司 一种制备卡非佐米无定型物的方法
WO2017032487A1 (fr) 2015-08-27 2017-03-02 Technische Universität München Inhibiteur de protéasome comprenant une fraction d'émission de signal
US20180362580A1 (en) 2015-12-11 2018-12-20 Mylan Laboratories Limited Crystalline and amorphous forms of carfilzomib
TWI636052B (zh) * 2015-12-31 2018-09-21 中化合成生技股份有限公司 無定形卡非佐米(i)的製備方法
WO2017147410A1 (fr) 2016-02-25 2017-08-31 Amgen Inc. Composés inhibant la protéine mcl-1
TWI759301B (zh) * 2016-05-24 2022-04-01 美商安美基公司 聚乙二醇化卡非佐米化合物
EP3494126A1 (fr) 2016-08-02 2019-06-12 Synthon BV Procédé de fabrication du carfilzomib
CR20190113A (es) 2016-08-05 2019-04-25 Amgen Inc Síntesis de (s)-2-amino-4-metil-1-((r)-2-metiloxirano-2-il)-pentan-1-ona y sales farmacéuticamente aceptables de la misma
US11078231B2 (en) 2016-09-14 2021-08-03 Fresenius Kabi Oncology Ltd Process for purification of carfilzomib intermediate
EP3512602B1 (fr) 2016-09-16 2024-03-27 HSF Pharmaceuticals Inhibiteurs des facteurs de choc thermique (hsf) et utilisations de ceux-ci
EP3330260A1 (fr) 2016-12-01 2018-06-06 Enantia, S.L. Procédé pour la préparation d'un intermédiaire pour la synthèse de i.a. carfilzomib
EP3694878A1 (fr) 2017-09-14 2020-08-19 GlaxoSmithKline Intellectual Property Development Limited Polythérapie pour le traitement du cancer
CA3082786A1 (fr) 2017-11-16 2019-05-23 Amgen Inc. Compositions stables de composes carfilzomib pegyles
WO2019113363A1 (fr) * 2017-12-08 2019-06-13 NeuroDiagnostics LLC Test d'expression génique de cycle cellulaire synchronisé pour la maladie d'alzheimer et procédés thérapeutiques associés
US10537585B2 (en) 2017-12-18 2020-01-21 Dexcel Pharma Technologies Ltd. Compositions comprising dexamethasone
US10689416B2 (en) * 2017-12-30 2020-06-23 Unity Biotechnology, Inc. Peptide-based proteasome inhibitors for treating conditions mediated by senescent cells and for treating cancer
WO2019133988A1 (fr) 2017-12-30 2019-07-04 Unity Biotechnology, Inc. Inhibiteurs de protéasome à base de peptides pour le traitement d'affections induites par des cellules sénescentes et pour le traitement du cancer
CN113286586A (zh) * 2018-06-22 2021-08-20 Ucl商业有限公司 新化合物
EP4041747A4 (fr) * 2019-10-11 2023-10-18 Mayo Foundation for Medical Education and Research Inhibiteurs de protéasome
WO2023220641A2 (fr) 2022-05-11 2023-11-16 Juno Therapeutics, Inc. Méthodes et utilisations associées à une thérapie par lymphocytes t et leur production
WO2023220655A1 (fr) 2022-05-11 2023-11-16 Celgene Corporation Méthodes pour surmonter la résistance aux médicaments par ré-sensibilisation de cellules cancéreuses à un traitement avec une thérapie antérieure par l'intermédiaire d'un traitement avec une thérapie par lymphocytes t
WO2024069240A2 (fr) 2022-09-29 2024-04-04 Takeda Pharmaceutical Company Limited Thérapie de combinaison de protéines de fusion se liant à cd38
WO2024097905A1 (fr) 2022-11-02 2024-05-10 Celgene Corporation Méthodes de traitement au moyen d'une thérapie par lymphocytes t et d'une thérapie d'entretien par agent immunomodulateur

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US569748A (en) 1896-10-20 Henry edmunds
US4733665C2 (en) 1985-11-07 2002-01-29 Expandable Grafts Partnership Expandable intraluminal graft and method and apparatus for implanting an expandable intraluminal graft
US4990448A (en) 1989-08-04 1991-02-05 Bristol-Myers Company Bu-4061T
US5071957A (en) * 1989-08-04 1991-12-10 Bristol-Myers Company Antibiotic BU-4061T
US5340736A (en) * 1991-05-13 1994-08-23 The President & Fellows Of Harvard College ATP-dependent protease and use of inhibitors for same in the treatment of cachexia and muscle wasting
WO1998010779A1 (fr) 1996-09-13 1998-03-19 New York University Methode pour traiter des maladies parasitaires avec des inhibiteurs de proteasome
US6099851A (en) * 1998-06-02 2000-08-08 Weisman; Kenneth M. Therapeutic uses of leuprolide acetate
US6462019B1 (en) 1998-07-10 2002-10-08 Osteoscreen, Inc. Inhibitors of proteasomal activity and production for stimulating bone growth
US6838436B1 (en) * 1998-07-10 2005-01-04 Osteoscreen Inc. Inhibitors of proteasomal activity for stimulating bone growth
US6902721B1 (en) * 1998-07-10 2005-06-07 Osteoscreen, Inc. Inhibitors of proteasomal activity for stimulating bone growth
US6204257B1 (en) * 1998-08-07 2001-03-20 Universtiy Of Kansas Water soluble prodrugs of hindered alcohols
US6492333B1 (en) 1999-04-09 2002-12-10 Osteoscreen, Inc. Treatment of myeloma bone disease with proteasomal and NF-κB activity inhibitors
US6831099B1 (en) * 1999-05-12 2004-12-14 Yale University Enzyme inhibition
EP1477180A1 (fr) 1999-10-20 2004-11-17 Osteoscreen, Inc. Inhibiteurs de l'activité de proteasome pour favoriser la croissance osseuse et la pousse des cheveux
AU2003219652A1 (en) 2002-01-08 2003-07-30 Eisai Co. Ltd. Eponemycin and epoxomicin analogs and uses thereof
US7232818B2 (en) * 2004-04-15 2007-06-19 Proteolix, Inc. Compounds for enzyme inhibition
AU2005238445B2 (en) * 2004-04-15 2012-05-03 Onyx Therapeutics, Inc. Compounds for enzyme inhibition
ES2510840T3 (es) 2004-05-10 2014-10-21 Onyx Therapeutics, Inc. Compuestos para la inhibición enzimática del proteosoma
WO2005111009A2 (fr) * 2004-05-10 2005-11-24 Proteolix, Inc. Synthese de ceto-epoxydes d'acides amines

Also Published As

Publication number Publication date
US20060030533A1 (en) 2006-02-09
US20160222057A1 (en) 2016-08-04
AU2005271232B2 (en) 2012-07-05
US20200071356A1 (en) 2020-03-05
ES2525248T3 (es) 2014-12-19
CY2016009I2 (el) 2016-08-31
US7491704B2 (en) 2009-02-17
AU2005271232A1 (en) 2006-02-16
CY1120677T1 (el) 2019-12-11
BRPI0514102B1 (pt) 2020-07-07
US7417042B2 (en) 2008-08-26
EP2270026B1 (fr) 2016-05-18
US20190211058A1 (en) 2019-07-11
SG10201701794UA (en) 2017-04-27
SI3101026T1 (en) 2018-08-31
KR20120135355A (ko) 2012-12-12
EP2270026A2 (fr) 2011-01-05
BRPI0514102B8 (pt) 2021-05-25
PL1781688T3 (pl) 2011-06-30
HK1231491A1 (zh) 2017-12-22
IL261892B (en) 2019-12-31
SI1781688T1 (sl) 2011-05-31
EP3101026A1 (fr) 2016-12-07
HK1103525A1 (en) 2007-12-21
JP2008509166A (ja) 2008-03-27
CA2589765A1 (fr) 2006-02-16
FR16C0017I1 (fr) 2016-06-24
IL221572A0 (en) 2012-10-31
NO341015B1 (no) 2017-08-07
HUE038005T2 (hu) 2018-09-28
ES2674277T3 (es) 2018-06-28
IL221572B (en) 2018-10-31
NO20170381A1 (no) 2007-04-16
PT1781688E (pt) 2011-04-05
LT3101026T (lt) 2018-07-10
US20150361134A1 (en) 2015-12-17
US20140342977A1 (en) 2014-11-20
DK1781688T3 (da) 2011-03-14
US20180170962A1 (en) 2018-06-21
EP2266999B1 (fr) 2014-09-24
NO20070965L (no) 2007-04-16
JP5394423B2 (ja) 2014-01-22
IL261892A (en) 2018-10-31
WO2006017842A1 (fr) 2006-02-16
PL3101026T3 (pl) 2018-12-31
LTPA2016010I1 (lt) 2016-04-25
NO344397B1 (no) 2019-11-25
BR122020008634B1 (pt) 2021-02-17
CA2589765C (fr) 2015-06-30
EP2270026A3 (fr) 2011-09-14
CY1116771T1 (el) 2016-08-31
US20220267372A1 (en) 2022-08-25
HK1152716A1 (zh) 2012-03-09
HK1152536A1 (en) 2012-03-02
HUS1600014I1 (hu) 2016-05-30
EP1781688B1 (fr) 2011-01-19
CY2016009I1 (el) 2016-08-31
US20070191284A1 (en) 2007-08-16
LTC1781688I2 (lt) 2017-09-25
FR16C0017I2 (fr) 2016-08-26
KR101354280B1 (ko) 2014-01-23
EP2266999A3 (fr) 2011-09-14
BR122020008634B8 (pt) 2021-07-27
JP2011148805A (ja) 2011-08-04
IL181127A (en) 2013-03-24
DK3101026T3 (en) 2018-06-18
JP4743720B2 (ja) 2011-08-10
US20050245435A1 (en) 2005-11-03
US7232818B2 (en) 2007-06-19
EP3101026B1 (fr) 2018-03-28
BRPI0514102A (pt) 2008-05-27
KR20070047780A (ko) 2007-05-07
PT3101026T (pt) 2018-08-03
SG155187A1 (en) 2009-09-30
DE602005026019D1 (de) 2011-03-03
ATE496062T1 (de) 2011-02-15
CN102286070B (zh) 2014-12-10
KR101544258B1 (ko) 2015-08-21
US20200325172A1 (en) 2020-10-15
US20210179663A1 (en) 2021-06-17
EP2266999A2 (fr) 2010-12-29
CN102286070A (zh) 2011-12-21
EP1781688A1 (fr) 2007-05-09
IL181127A0 (en) 2007-07-04
KR20130080064A (ko) 2013-07-11

Similar Documents

Publication Publication Date Title
LU93015I2 (fr) Carfilzomib eventuellement sous forme d'un sel pharmaceutiquement acceptable
IL217210A0 (en) Compounds for proteasome enzyme inhibition
EP2564834A3 (fr) Composés pour lýinhibition dýune enzyme du protéasome
HK1121172A1 (en) Compounds for enzyme inhibition
WO2008140782A3 (fr) Composés d'inhibition enzymatique